388 related articles for article (PubMed ID: 31735168)
21. Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.
Seino M; Okada M; Shibuya K; Seino S; Suzuki S; Ohta T; Kurachi H; Kitanaka C
Anticancer Res; 2014 Sep; 34(9):4723-31. PubMed ID: 25202050
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
23. CD166 promotes the cancer stem-like properties of primary epithelial ovarian cancer cells.
Kim DK; Ham MH; Lee SY; Shin MJ; Kim YE; Song P; Suh DS; Kim JH
BMB Rep; 2020 Dec; 53(12):622-627. PubMed ID: 32843129
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
25. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
[TBL] [Abstract][Full Text] [Related]
26. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines.
Shu X; Liu H; Pan Y; Sun L; Yu L; Sun L; Yang Z; Ran Y
Mol Cell Biochem; 2019 Sep; 459(1-2):35-47. PubMed ID: 31073886
[TBL] [Abstract][Full Text] [Related]
27. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
28. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
29. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
30. Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas.
Buishand FO; Arkesteijn GJ; Feenstra LR; Oorsprong CW; Mestemaker M; Starke A; Speel EJ; Kirpensteijn J; Mol JA
Stem Cells Dev; 2016 Jun; 25(11):826-35. PubMed ID: 27049037
[TBL] [Abstract][Full Text] [Related]
31. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S
Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199
[TBL] [Abstract][Full Text] [Related]
33. The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression-ALDH1A1, CD133, CD44-For Survival and Long-Term Follow-Up of Ovarian Cancer Patients.
Izycka N; Rucinski M; Andrzejewska M; Szubert S; Nowak-Markwitz E; Sterzynska K
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768723
[TBL] [Abstract][Full Text] [Related]
34. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
36. Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Belotte J; Fletcher NM; Alexis M; Morris RT; Munkarah AR; Diamond MP; Saed GM
Reprod Sci; 2015 Jan; 22(1):38-46. PubMed ID: 25038052
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
39. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
40. Metformin targets gastric cancer stem cells.
Courtois S; Durán RV; Giraud J; Sifré E; Izotte J; Mégraud F; Lehours P; Varon C; Bessède E
Eur J Cancer; 2017 Oct; 84():193-201. PubMed ID: 28822889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]